TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reactogenicity & Immunogenicity Study of Two Doses of GSK Biologicals' Oral Live Attenuated HRV Vaccine Co-administered With Either OPV or IPV in Healthy Infants (Approximately 5-10 Weeks Old) in South Africa
Brief Summary: "The primary objective of this study was to demonstrate that co-administering HRV vaccine with OPV does not induce a significant decrease in poliovirus immune response one month after the third dose of combined vaccines.

The primary objective was reached if one month after the third dose of polio vaccine, upper limit of the 95% CI for the difference in Seroprotection rate between the group B and C pooled and (minus) the group A was below 10% for each polio serotype."


Options:
A: Intervention Type: BIOLOGICAL; Name: HRV vaccine; Assigned to Arm(s): N/A
B: Arm Label: Oral Rotavirus Vaccine 116E (ORV 116E); Type: EXPERIMENTAL; Interventions: Biological: ORV 116E | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: ORV 116E; Assigned to Arm(s): Oral Rotavirus Vaccine 116E (ORV 116E) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Rotavirus vaccine (BRV-PV); Type: EXPERIMENTAL; Interventions: Biological: Rotavirus vaccine (BRV-PV) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Rotavirus vaccine (BRV-PV); Assigned to Arm(s): Rotavirus vaccine (BRV-PV) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: BIOLOGICAL; Name: Rotavirus (vaccine); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reactogenicity & Immunogenicity Study of Two Doses of GSK Biologicals' Oral Live Attenuated HRV Vaccine Co-administered With Either OPV or IPV in Healthy Infants (Approximately 5-10 Weeks Old) in South Africa
Brief Summary: "The primary objective of this study was to demonstrate that co-administering HRV vaccine with OPV does not induce a significant decrease in poliovirus immune response one month after the third dose of combined vaccines.

The primary objective was reached if one month after the third dose of polio vaccine, upper limit of the 95% CI for the difference in Seroprotection rate between the group B and C pooled and (minus) the group A was below 10% for each polio serotype."


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: Rotateq™ | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Comparator: Placebo | Intervention Type: BIOLOGICAL; Name: Rotateq™; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Comparator: Placebo; Assigned to Arm(s): 2
B: Arm Label: Rotarix 3-Dose Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™ | Arm Label: Rotarix 2-Dose Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™, Biological: Placebo | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Rotarix™; Assigned to Arm(s): Rotarix 2-Dose Group, Rotarix 3-Dose Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group, Rotarix 2-Dose Group
C: Intervention Type: BIOLOGICAL; Name: Rotavirus; Assigned to Arm(s): N/A
D: Intervention Type: BIOLOGICAL; Name: Rotavirus (vaccine); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sirolimus (Rapamune®) for Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD): a Randomized Controlled Study.
Brief Summary: The aim of our study is to investigate whether Rapamune used at a low dose (2 mg/d) retards cyst growth and slows renal functional deterioration in patients with ADPKD.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sirolimus | Intervention Type: DRUG; Name: Sirolimus; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Standard; Assigned to Arm(s): 1
B: Arm Label: Tolvaptan 45/15 mg/day orally for up to 4 years; Type: EXPERIMENTAL; Interventions: Drug: Tolvaptan | Arm Label: Tolvaptan 60/30 mg/day orally for up to 4 years; Type: EXPERIMENTAL; Interventions: Drug: Tolvaptan | Intervention Type: DRUG; Name: Tolvaptan; Assigned to Arm(s): Tolvaptan 45/15 mg/day orally for up to 4 years, Tolvaptan 60/30 mg/day orally for up to 4 years
C: Arm Label: Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Everolimus | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus
D: Arm Label: Tolvaptan; Type: EXPERIMENTAL; Interventions: Drug: Tolvaptan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tolvaptan; Assigned to Arm(s): Tolvaptan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Clinical Trial to Study the Effect of Extended Release Niacin on Endothelial Function, Oxidative Stress and Endothelial Progenitor Cells in Patients With the Metabolic Syndrome.
Brief Summary: The aim of the present study is to characterize novel mechanisms whereby HDL may exert potent vasculoprotective effects independent of reverse cholesterol transport, in particular the effect of HDL on the regulation of the vascular NAD(P)H oxidase enzyme system, a major vascular source of superoxide, known to be important for endothelial dysfunction. In addition, the present study will characterize the effect of HDL on endothelial progenitor cell (EPC) mobilization, nitric oxide production and in vivo regenerative capacity.


Options:
A: Intervention Type: DRUG; Name: niacin (+) laropiprant (+) simvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: niacin (+) laropiprant; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: simvastatin; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Niacin Extended-Release and simvastatin Tablets; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: OTHER; Interventions: Drug: ER niacin/laropiprant | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator : placebo (unspecified) | Intervention Type: DRUG; Name: ER niacin/laropiprant; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Comparator : placebo (unspecified); Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Extended-Release Niacin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Extended-Release Niacin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Insulin Analogues and Human Insulin on the Incidence of Severe Hypoglycaemia in Hypoglycaemia Prone Type 1 Diabetic Patients
Brief Summary: Severe hypoglycaemia is hampering the lives of many diabetic patients. The effect on the occurrence of severe hypoglycaemia during two different insulin regimens are to be investigated. In total, 250 hypoglycaemia prone type 1 diabetic patients will be randomised to receive analogue and human insulin for one year in random order. Outcomes will be number of episodes of severe hypoglycaemia


Options:
A: Arm Label: IDegAsp OD; Type: EXPERIMENTAL; Interventions: Drug: insulin degludec/insulin aspart, Drug: insulin aspart | Arm Label: IDet; Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin detemir, Drug: insulin aspart | Intervention Type: DRUG; Name: insulin degludec/insulin aspart; Assigned to Arm(s): IDegAsp OD | Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): IDet | Intervention Type: DRUG; Name: insulin aspart; Assigned to Arm(s): IDegAsp OD | Intervention Type: DRUG; Name: insulin aspart; Assigned to Arm(s): IDet
B: Intervention Type: BEHAVIORAL; Name: Insulin; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: human insulin /insulin isophane | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: insulin levemir / aspart | Intervention Type: DRUG; Name: insulin levemir / aspart; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: human insulin /insulin isophane; Assigned to Arm(s): 1
D: Arm Label: insulin detemir; Type: EXPERIMENTAL; Interventions: Drug: insulin detemir, Drug: insulin aspart | Arm Label: NPH insulin; Type: EXPERIMENTAL; Interventions: Drug: insulin NPH, Drug: insulin aspart | Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): insulin detemir | Intervention Type: DRUG; Name: insulin NPH; Assigned to Arm(s): NPH insulin | Intervention Type: DRUG; Name: insulin aspart; Assigned to Arm(s): NPH insulin, insulin detemir

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Coordinated Anxiety Learning and Management (CALM): Improving Primary Care Anxiety Outcomes
Brief Summary: This study will compare the effectiveness of an intervention strategy for the treatment of people with post traumatic stress disorder, generalized anxiety disorder, panic disorder, and social anxiety disorder in the primary care setting.


Options:
A: Arm Label: Collaborative Care; Type: EXPERIMENTAL; Interventions: Behavioral: Collaborative Care Treatment | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care Treatment | Intervention Type: BEHAVIORAL; Name: Collaborative Care Treatment; Assigned to Arm(s): Collaborative Care | Intervention Type: BEHAVIORAL; Name: Usual Care Treatment; Assigned to Arm(s): Usual Care
B: Arm Label: Assistance with Pain Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Assistance with Pain treatment | Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Assistance with Pain treatment; Assigned to Arm(s): Assistance with Pain Treatment
C: Intervention Type: BEHAVIORAL; Name: Program to Encourage Active, Rewarding Lives (PEARL); Assigned to Arm(s): N/A
D: Arm Label: CALM Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive-behavioral therapy, Drug: Psychotropic medication optimization | Arm Label: Treatment as Usual (TAU); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as Usual | Intervention Type: BEHAVIORAL; Name: Cognitive-behavioral therapy; Assigned to Arm(s): CALM Intervention | Intervention Type: DRUG; Name: Psychotropic medication optimization; Assigned to Arm(s): CALM Intervention | Intervention Type: BEHAVIORAL; Name: Treatment as Usual; Assigned to Arm(s): Treatment as Usual (TAU)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Coordinated Anxiety Learning and Management (CALM): Improving Primary Care Anxiety Outcomes
Brief Summary: This study will compare the effectiveness of an intervention strategy for the treatment of people with post traumatic stress disorder, generalized anxiety disorder, panic disorder, and social anxiety disorder in the primary care setting.


Options:
A: Arm Label: Collaborative group; Type: N/A; Interventions: Behavioral: Breakthrough collaborative | Arm Label: usual care group; Type: N/A; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Breakthrough collaborative; Assigned to Arm(s): Collaborative group
B: Arm Label: Depression CAREPATH; Type: EXPERIMENTAL; Interventions: Other: Depression CAREPATH | Arm Label: Usual Care; Type: OTHER; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: Depression CAREPATH; Assigned to Arm(s): Depression CAREPATH | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
C: Arm Label: CALM Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive-behavioral therapy, Drug: Psychotropic medication optimization | Arm Label: Treatment as Usual (TAU); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as Usual | Intervention Type: BEHAVIORAL; Name: Cognitive-behavioral therapy; Assigned to Arm(s): CALM Intervention | Intervention Type: DRUG; Name: Psychotropic medication optimization; Assigned to Arm(s): CALM Intervention | Intervention Type: BEHAVIORAL; Name: Treatment as Usual; Assigned to Arm(s): Treatment as Usual (TAU)
D: Arm Label: Arm 1 Telemedicine Outreach for PTSD; Type: EXPERIMENTAL; Interventions: Other: Telemedicine Outreach for PTSD | Arm Label: Arm 2 Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Telemedicine Outreach for PTSD; Assigned to Arm(s): Arm 1 Telemedicine Outreach for PTSD

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fluid Shift in Patients Treated With Therapeutic Hypothermia After Cardiac Arrest, and How do They Manage Life Afterwards?
Brief Summary: Therapeutic hypothermia after cardiac arrest har shown to improve the rate of survival in a significant way. However hypothermia also causes leak of fluid into the surrounding tissue. This edema could lead to damage to the same tissue, not beneficial for the patients. We therefore try to evaluate if hyperosmolar, hyperoncotic fluid as an alternative to std. treatment (NaCl/RA)could affect the edema in a positive way, and result to a better outcome neurological for the patients.


Options:
A: Intervention Type: DRUG; Name: HyperHAES vs. RA-solution/NaCl; Assigned to Arm(s): N/A
B: Arm Label: Voluven; Type: ACTIVE_COMPARATOR; Interventions: Drug: Resuscitation (Voluven) | Arm Label: Saline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Resuscitation (Saline) | Intervention Type: DRUG; Name: Resuscitation (Voluven); Assigned to Arm(s): Voluven | Intervention Type: DRUG; Name: Resuscitation (Saline); Assigned to Arm(s): Saline
C: Arm Label: Voluven® Arm; Type: EXPERIMENTAL; Interventions: Drug: 6 % Hydroxyethylstarch 130/0.4 = "Voluven®" | Arm Label: 0.9 % NaCl; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.9 % NaCl | Intervention Type: DRUG; Name: 6 % Hydroxyethylstarch 130/0.4 = "Voluven®"; Assigned to Arm(s): Voluven® Arm | Intervention Type: DRUG; Name: 0.9 % NaCl; Assigned to Arm(s): 0.9 % NaCl
D: Arm Label: Hydroxy-ethyl starch; Type: EXPERIMENTAL; Interventions: Drug: 6% Hydroxy-ethyl starch (130/0.4) | Arm Label: Saline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: 6% Hydroxy-ethyl starch (130/0.4); Assigned to Arm(s): Hydroxy-ethyl starch | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Saline

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fluid Shift in Patients Treated With Therapeutic Hypothermia After Cardiac Arrest, and How do They Manage Life Afterwards?
Brief Summary: Therapeutic hypothermia after cardiac arrest har shown to improve the rate of survival in a significant way. However hypothermia also causes leak of fluid into the surrounding tissue. This edema could lead to damage to the same tissue, not beneficial for the patients. We therefore try to evaluate if hyperosmolar, hyperoncotic fluid as an alternative to std. treatment (NaCl/RA)could affect the edema in a positive way, and result to a better outcome neurological for the patients.


Options:
A: Arm Label: Hydroxy-ethyl starch; Type: EXPERIMENTAL; Interventions: Drug: 6% Hydroxy-ethyl starch (130/0.4) | Arm Label: Saline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: 6% Hydroxy-ethyl starch (130/0.4); Assigned to Arm(s): Hydroxy-ethyl starch | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Saline
B: Arm Label: Voluven; Type: ACTIVE_COMPARATOR; Interventions: Drug: Resuscitation (Voluven) | Arm Label: Saline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Resuscitation (Saline) | Intervention Type: DRUG; Name: Resuscitation (Voluven); Assigned to Arm(s): Voluven | Intervention Type: DRUG; Name: Resuscitation (Saline); Assigned to Arm(s): Saline
C: Intervention Type: DRUG; Name: HyperHAES vs. RA-solution/NaCl; Assigned to Arm(s): N/A
D: Arm Label: Voluven® Arm; Type: EXPERIMENTAL; Interventions: Drug: 6 % Hydroxyethylstarch 130/0.4 = "Voluven®" | Arm Label: 0.9 % NaCl; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.9 % NaCl | Intervention Type: DRUG; Name: 6 % Hydroxyethylstarch 130/0.4 = "Voluven®"; Assigned to Arm(s): Voluven® Arm | Intervention Type: DRUG; Name: 0.9 % NaCl; Assigned to Arm(s): 0.9 % NaCl

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Clinical Trial of the Effectiveness of Base-in Prism Reading Glasses Vs. Placebo Reading Glasses for Symptomatic Convergence Insufficiency in Children
Brief Summary: This study is designed to compare the use of special prism glasses to placebo treatment for children with symptomatic convergence insufficiency.


Options:
A: Intervention Type: BEHAVIORAL; Name: Home-based Pencil Push-Up Therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Home-based Pencil Push-ups with Computer Vision Therapy/Orthoptics; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Office-based Vision Therapy/Orthoptics; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Placebo Office-based Vision Therapy/Orthoptics; Assigned to Arm(s): N/A
B: Arm Label: Office-based verg/accomm therapy (OBVAT); Type: EXPERIMENTAL; Interventions: Procedure: Office-based vergence/accommodative therapy | Arm Label: Office-based placebo therapy (OBPT); Type: PLACEBO_COMPARATOR; Interventions: Procedure: Office-based vergence/accommodative therapy | Intervention Type: PROCEDURE; Name: Office-based vergence/accommodative therapy; Assigned to Arm(s): Office-based placebo therapy (OBPT), Office-based verg/accomm therapy (OBVAT)
C: Arm Label: Computer-based therapy (CBT); Type: ACTIVE_COMPARATOR; Interventions: Other: Active home-based computer vergence/accommodative therapy, Procedure: Placebo yoked prism flippers | Arm Label: Near target push-up (NTP); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Near target push-ups, Other: Placebo home-based computer vergence/accommodative therapy | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo home-based computer vergence/accommodative therapy, Procedure: Placebo yoked prism flippers | Intervention Type: OTHER; Name: Active home-based computer vergence/accommodative therapy; Assigned to Arm(s): Computer-based therapy (CBT) | Intervention Type: PROCEDURE; Name: Near target push-ups; Assigned to Arm(s): Near target push-up (NTP) | Intervention Type: OTHER; Name: Placebo home-based computer vergence/accommodative therapy; Assigned to Arm(s): Near target push-up (NTP), Placebo | Intervention Type: PROCEDURE; Name: Placebo yoked prism flippers; Assigned to Arm(s): Computer-based therapy (CBT), Placebo
D: Intervention Type: PROCEDURE; Name: Base-in prism glasses for reading; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Placebo reading glasses; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Strategies for the Control of Blinding Trachoma: Effect of Fly Spray
Brief Summary: The purpose of this community-based randomized trial was to determine, in trachoma hyper-endemic communities of Tanzania, the added value of intensive spraying to control flies on the fly population and on trachoma and ocular chlamydia infection at 6 months and one year after mass antibiotic treatment.


Options:
A: Arm Label: Biannual mass oral azithromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Biannual mass oral placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Biannual mass oral azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Biannual mass oral placebo
B: Intervention Type: DRUG; Name: Mass treatment with oral azithromycin to an entire village; Assigned to Arm(s): N/A
C: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: intervention; Type: ACTIVE_COMPARATOR; Interventions: Procedure: 10% permethrin in water applied as low volume spray | Intervention Type: PROCEDURE; Name: 10% permethrin in water applied as low volume spray; Assigned to Arm(s): intervention
D: Arm Label: ≥90% coverage with azithromycin target; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: 80%-89% coverage with azithromycin target; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: ≥90% coverage with azithromycin , treatment based; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: 80%-89% coverage with azithromycin : treatment based; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): 80%-89% coverage with azithromycin target, ≥90% coverage with azithromycin target | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): 80%-89% coverage with azithromycin : treatment based, ≥90% coverage with azithromycin , treatment based

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial of Antibiotics to Reduce Recurrent Trichiasis (STAR)
Brief Summary: Trachoma, an ocular infection caused by C. trachomatis, is the second leading cause of blindness worldwide.Years of repeated infection with C. trachomatis cause the eyelid to scar and contract and ultimately to rotate inward such that eyelashes rub against the eyeball and abrade the cornea (trichiasis). The World Health Organization (WHO) has endorsed a multi-faceted strategy to combat trachoma, which includes surgery to correct trichiasis. Despite this encouraging news, under the best of circumstances the recurrence rate of trichiasis following surgery is disappointingly high. The objective of our project is to conduct a randomized, controlled clinical trial of post-surgical antibiotic treatment, comparing oral azithromycin to topical tetracycline, for trichiasis surgical patients in Ethiopia with the goal of determining the impact of treatment on rates of trichiasis recurrence at one and two years.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Procedure: Trichiasis surgery | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Epilation | Intervention Type: PROCEDURE; Name: Trichiasis surgery; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Epilation; Assigned to Arm(s): B
B: Arm Label: TT Clamp; Type: EXPERIMENTAL; Interventions: Device: TT Clamp | Arm Label: Standard BLTR Technique; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard BLTR Technique | Intervention Type: DEVICE; Name: TT Clamp; Assigned to Arm(s): TT Clamp | Intervention Type: PROCEDURE; Name: Standard BLTR Technique; Assigned to Arm(s): Standard BLTR Technique
C: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: topical tetracycline | Arm Label: Intervention 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: azithromycin | Arm Label: Intervention 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: azithromycin | Intervention Type: DRUG; Name: azithromycin; Assigned to Arm(s): Intervention 1, Intervention 2 | Intervention Type: DRUG; Name: topical tetracycline; Assigned to Arm(s): Control
D: Arm Label: Vicryl Suture; Type: EXPERIMENTAL; Interventions: Procedure: Trichiasis surgery with absorbable sutures | Arm Label: Silk Suture; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Trichiasis surgery with non-absorbable sutures | Intervention Type: PROCEDURE; Name: Trichiasis surgery with absorbable sutures; Assigned to Arm(s): Vicryl Suture | Intervention Type: PROCEDURE; Name: Trichiasis surgery with non-absorbable sutures; Assigned to Arm(s): Silk Suture

Answer: C